Helping to change scientists' thinking about how the heart is formed, researchers at Children's Hospital Boston have identified a type of stem cell that is the precursor to at least two main cell types that form the heart. This single cardiac progenitor cell gives rise to both myocardial cells, which form the beating muscle and electrically conductive tissue of the heart, and to the vascular smooth muscle cells that line the heart's blood vessels. This cell is responsible for the formation of the left-sided chambers of the heart, the first chambers to form in the embryo.
Working in parallel, a separate team at Massachusetts General Hospital discovered a related progenitor cell that gives rise to the right-sided heart chambers, forming myocardial cells, smooth muscle cells, and endothelial cells.
Since these different cell types were thought to have separate ancestors, the studies offer a new understanding of the development of the mammalian heart – the earliest organ to develop, and the one most susceptible to congenital defects. They also bring researchers a step closer to being able to regenerate tissues to repair congenital heart defects in children and damage caused by heart attacks in adults.
The two laboratories are now trying to determine the relationship between the two types of progenitor cells discovered. Both papers will appear in the December 15 issue of the journal Cell, which was published online November 22.
The Children's team, led by senior investigator Stuart H. Orkin, MD, a Howard Hughes Medical Institute investigator, and Sean Wu, MD, PhD, the study's first author, first worked with mouse embryonic stem cells in culture. They allowed the cells to differentiate in a Petri dish, then isolated a relatively rare subtype of cell (just 1 percent of the cells in the dish) that were poised to begin developing along a cardiac pathway. The presence of these cardiac progenitors was indicated by a green fluorescent protein, which lit up when a gene called Nkx2.5 was activated. Orkin and Wu then showed that these cells further differentiated into both myocardial cells and smooth-muscle cells.
Next, using the same fluorescent "tags," Orkin and Wu isolated the same cardiac progenitor cells directly from live mice early in embryonic development.
"There have been a number of publications about stem-like cells in the heart, but these are the first studies to identify such cells during embryonic development, and to show that they give rise to different cell types," says Orkin, who is the David G. Nathan Professor of Pediatrics at Harvard Medical School and also chairs the department of pediatric oncology at Dana-Farber Cancer Institute. He and Wu are also members of the Harvard Stem Cell Institute.
"Previously, it had been thought that each cell type in the heart had a different origin. Now, it's pretty clear that some have common origins," Orkin adds. "This changes the notion of how the heart develops. Instead of multiple different cell types migrating and coming together to form the heart, the heart comes from stem cells that give rise to multiple cell types in the same local environment – a simpler way of building the organ. And because these cells can make multiple cell types, they could be more useful in repairing the heart than any single kind of cell."
Orkin cautions that there are many steps before cardiac progenitor cells could be used to repair a human heart. The studies were done in mice, and it's still unknown what factors make embryonic stem cells differentiate into cardiac progenitors, or what factors make cardiac progenitors differentiate into more specialized heart cells. But ultimately, cardiac surgeons at Children's hope to be able to use cardiac stem cells to repair congenital heart defects such as defective heart valves, missing or undeveloped arteries, or underdeveloped heart chambers.
"If you understand the process of how things develop from very primitive embryonic stem cells to fully differentiated tissue, you have the potential to duplicate that process in the lab and make a tissue that a patient might need," says John Mayer, MD, a cardiovascular surgeon at Children's who is developing tissue-engineering techniques to create biological replacements for failing heart valves. Felix Engel, PhD, a cardiology researcher at Children's, recently got heart muscle cells to replicate, a feat that normally occurs only during embryonic development and represents another approach to repairing injured heart muscle. By apparently stimulating tissue regeneration, he was also able improve heart function after a simulated heart attack.
The study by Orkin and Wu was funded by the National Institutes of Health, an American College of Cardiology Foundation/Pfizer Postdoctoral Fellowship in Cardiovascular Medicine, the de Gunzburg Family Foundation and the Howard Hughes Medical Institute.
Children's Hospital Boston is home to the world's largest research enterprise based at a pediatric medical center, where its discoveries have benefited both children and adults since 1869. More than 500 scientists, including eight members of the National Academy of Sciences, 11 members of the Institute of Medicine and 10 members of the Howard Hughes Medical Institute comprise Children's research community. Founded as a 20-bed hospital for children, Children's Hospital Boston today is a 347-bed comprehensive center for pediatric and adolescent health care grounded in the values of excellence in patient care and sensitivity to the complex needs and diversity of children and families. Children's also is the primary pediatric teaching affiliate of Harvard Medical School. For more information about the hospital and its research visit: www.childrenshospital.org/newsroom.
Last reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
Published on PsychCentral.com. All rights reserved.